Basilea Pharmaceutica AG
Basilea Pharmaceutica AG (BPMUF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bpmuf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Basilea Pharmaceutica AG (BPMUF) measures how much investors pay for each dollar of the company's trailing earnings. BPMUF's current PE ratio of 18.55x is calculated by dividing its stock price of $65.10 by its TTM earnings per share of $2.65. −32.4% discount vs 5Y avg 27.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%27.7x
MedianQ3 · 75%46.9x
Max
At 18.55x, BPMUF's current P/E is within its average historical range over the past 4 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Basilea Pharmaceutica AGYou BPMUF | $806M | 18.55x | — | $2.65 |
 Beijing Tong Ren Tang Chinese Medicine Company Limited BJTRF | $536M | 10.64x | — | $0.47 |
 Avisa Diagnostics Inc. FOGCF | $0M | N/A | — | -$0.14 |
 GenSight Biologics S.A. GSGTF | $31M | N/A | — | -$0.08 |
 Valneva SE INRLF | $531M | N/A | — | -$0.68 |
 MedinCell S.A. MDCLF | $1.2B | N/A | — | -$0.63 |
 PureTech Health plc PTCHF | $438M | N/A | — | -$0.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 15.24x | $3.29 | +104.0% | |
2024-12-31 FY2024 | 7.47x | $6.42 | -81.4% | |
2023-12-31 FY2023 | 40.08x | $0.86 | -14.6% | |
2022-12-31 FY2022 | 46.92x | $1.02 | — | |
2021-12-31 FY2021 | — | $-0.58 | — | |
2020-12-31 FY2020 | — | $-1.43 | — | |
2019-12-31 FY2019 | — | $-2.08 | — | |
2018-12-31 FY2018 | — | $-2.89 | — | |
2017-12-31 FY2017 | — | $-1.79 | — | |
2016-12-31 FY2016 | — | $-5.07 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Basilea Pharmaceutica AG (BPMUF) measures how much investors pay for each dollar of the company's trailing earnings. BPMUF's current PE ratio of 18.55x is calculated by dividing its stock price of $65.10 by its TTM earnings per share of $2.65.
Frequently asked questions
BPMUF pe ratio · 6 questionsBPMUF's current PE ratio is 18.55x as of 2026-06-09, based on a stock price of $65.10 and TTM EPS of $2.65. Data sourced from Financial Modeling Prep via BPMUF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Basilea Pharmaceutica AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09